Patent application number | Description | Published |
20100154325 | WAVEGUIDE FOR A RADIO FREQUENCY DOOR - A waveguide for a radio frequency door like that used in a medical imaging room allows intravenous lines and electrical conduits to be inserted through the door frame without being disconnected from the patient. The waveguide includes a door frame section, and a removable, telescoping or pivoting movable member that cooperates with the door frame section to retain the conduits. The movable member is positioned away from the door frame section during insertion and removal of the conduits from the door frame section, and is positioned adjacent the door frame section when the conduits are being retained. The dimensions and materials of the waveguide are selected to achieve attenuation of electromagnetic interference. | 06-24-2010 |
20120182768 | LED REPLACEMENT BULB FOR USE IN LOW EM ROOM - An LED replacement light bulb for use in a standard AC light bulb socket is provided. The light bulb includes a body, a heat sink portion and an end cap arranged to receive DC electrical current from the AC light bulb socket where the AC electrical system has been converted to a DC electrical system. The LED replacement bulb includes a base and wires connecting the base to a plurality of LEDs or to an LED board. A quick disconnect is disposed between the base and the plurality of LEDS or the LED board to allow for easy removal and replacement of the LEDs or of the LED board. In one preferred embodiment, a lens cover is provided with stand-off legs to avoid metal to metal contact between the bulb and its surrounding lighting fixture. | 07-19-2012 |
20140121453 | METHOD, SYSTEM AND SOFTWARE PRODUCT FOR CREATING VARIABLE ENVIRONMENTS IN MEDICAL DIAGNOSTIC IMAGING ROOMS - A method, system and software product are provided such that a patient in an MRI suite can select and enjoy personalized lighting, music, images and video with a touch screen for a program that is displayed on a system interactive digital unit or device. A wide and advanced variety of pre-programmed themes can be provided with the system, as is the option of creating customized content by the healthcare provider. Image panels help to “transport” the patient “away” from the confining space in the magnet bore of the MRI scanner, moving the patient's focus from the scanner to his or her surroundings. A ceiling image panel displays images of the patient's choice. Patients can also “dock” their own electronic device to enjoy their own audio visual content. The lighting of the suite can be returned to normal lighting when required and then back to the patient's original selections. | 05-01-2014 |
Patent application number | Description | Published |
20100297088 | Methods for Culturing Minimally-Passaged Fibroblasts and Uses Thereof - The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times. | 11-25-2010 |
20100303770 | METHODS FOR CULTURING DERMAL CELLS FOR TREATMENT OF SKIN INJURIES SUCH AS BURNS - The present invention relates to novel methods of growing or otherwise producing unpassaged or minimally-passaged dermal cells from a small biopsy specimen for treating skin injuries significantly larger than the biopsy. | 12-02-2010 |
20130224160 | Treatment of Vocal Cords with Autologous Dermal Fibroblast Formulation - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three times approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×10 | 08-29-2013 |
20140335057 | Methods For Culturing Minimally-Passaged Fibroblasts And Uses Thereof - The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is needed directly into a large tissue culture flask, and passaged so more than three times. | 11-13-2014 |
20140348801 | Treatment of Vocal Cords With Autologous Dermal Fibroblast Formulation - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three tunes approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×10 | 11-27-2014 |
Patent application number | Description | Published |
20110274665 | DOSAGE UNIT FORMULATIONS OF AUTOLOGOUS DERMAL FIBROBLASTS - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×10 | 11-10-2011 |
20120219634 | TOPICAL DERMAL FORMULATIONS - An autologous topical formulation containing conditioned medium obtained from culture of autologous fibroblasts has been developed. Unlike other topical formulations, it is autologous since it is derived solely from cells obtained by the person who is to use the formulation. This avoids any possible reaction with proteins derived from the cells. Preferred formulations include gels, creams, lotions, and ointments. The topical formulations of conditioned medium obtained by culturing autologous dermal fibroblasts are topically administered to individuals for the prevention and treatment of scarring, reduction in signs of aging, and improvement in quality of skin. | 08-30-2012 |
20130295061 | Dosage Unit Formulations of Autologous Dermal Fibroblasts - Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own skin using current good manufacturing practices (CGMP), and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL, of cells at a concentration of from 1.0-2.0×10 | 11-07-2013 |
20140072611 | Methods and Compositions for Treating Post-Cardial Infarction Damage - Compositions for delaying, attenuating or preventing cardiac remodeling following cardiac injury contain fibroblast cells in a dosage providing an effective amount to delay, attenuate or prevent cardiac remodeling following cardiac injury. These cells are obtained by biopsy, preferably from the patient, then cultured and proliferated prior to use. It has been discovered that certain subpopulations of these cells are even better suited for repair or regeneration of tissue, the cells exhibiting properties similar to stem cells or multipotent cells. In a preferred embodiment, the cells are administered to delay, attenuate or prevent cardiac remodeling following cardiac injury. | 03-13-2014 |
20140099383 | Topical Dermal Formulations - An autologous topical formulation containing conditioned medium obtained from culture of autologous fibroblasts has been developed. Unlike other topical formulations, it is autologous since it is derived solely from cells obtained by the person who is to use the formulation. This avoids any possible reaction with proteins derived from the cells. Preferred formulations include gels, creams, lotions, and ointments. The topical formulations of conditioned medium obtained by culturing autologous dermal fibroblasts are topically administered to individuals for the prevention and treatment of scarring, reduction in signs of aging, and improvement in quality of skin. | 04-10-2014 |